Patients with castration-resistant prostate cancer (CRPC), who progress after docetaxel therapy, had until very recently, only a few therapeutic options.
Recent advances in this field brought about new perspectives in the treatment of this disease. Molecular, basic, and translational research has given us a better understanding on the mechanisms of CRPC. This great investment has turned into a more rational approach to the development of new drugs. Some of the new treatments are already available to our patients outside clinical trials and may include inhibitors of androgen biosynthesis; new chemotherapy agents; bone-targeted therapy; and immunotherapy. This paper aims to review the mechanisms of prostate cancer resistance, possible therapeutic targets, as well as new options to treat CRPC.
Written by:
Amaral TM, Macedo D, Fernandes I, Costa L. Are you the author?
Oncology Division, Hospital de Santa Maria, Instituto de Medicina Molecular, 1649-039 Lisbon, Portugal.
Reference: Prostate Cancer. 2012;2012:327253.
doi: 10.1155/2012/327253
PubMed Abstract
PMID: 22530130
UroToday.com Prostate Cancer Section